Recent studies also indicated that dysregulation of the immune system including alteration in the number or function of immune cells, the release of chemokine and cytokine, and expression of inhibitory receptors or their ligands can lead to the progression of hepatocellular carcinoma.5, 6 Moreover, immune checkpoint inhibitors that specifically target PD1/PD‐L1 had indicated a manageable safety and lasting response in advanced hepatocellular carcinoma.7 So far, there is no research which has constructed a prognosis signature by using immune‐related gene. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.